TECXTectonic Therapeutic, Inc.同业对比
Tectonic Therapeutic, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TECX本股 | $389M#6 | — | 1.7x#5 | — | — | -27.9%#10 | — | -33125.9%#13 | -713.5%#6 | — | 18.6%#5 | — |
| AURA | $675M#1 | — | 2.1x#8 | — | — | -22.2%#8 | — | -33.7%#4 | — | — | 15.0%#7 | — |
| FDMT | — | — | — | — | 230194.6%#1 | 12.9%#6 | -187.2%#4 | -34.4%#5 | -44.7%#3 | — | 13.0%#8 | — |
| GRML | $616M#2 | — | 10.6x#12 | — | — | -71.6%#12 | — | -18.2%#3 | -14.6%#2 | — | -83.6%#14 | — |
| RGNX | $510M#3 | — | 7.1x#11 | 3.0x#3 | 104.5%#4 | 14.6%#5 | -94.6%#3 | -270.2%#12 | — | — | -33.0%#13 | — |
| EDIT | $416M#4 | — | 4.0x#10 | 10.3x#5 | 25.4%#5 | 32.5%#3 | -394.9%#7 | -152.0%#11 | — | — | -2.2%#10 | — |
| ALLO | $404M#5 | — | 0.9x#2 | — | -100.0%#9 | 25.9%#4 | — | -43.8%#7 | — | — | 6.8%#9 | — |
| ZURA | $385M#7 | — | 3.8x#9 | — | — | -31.0%#11 | — | -67.6%#9 | — | — | 16.1%#6 | — |
| CCCC | $381M#8 | — | 1.5x#4 | 10.6x#6 | 1.0%#7 | 0.3%#7 | -320.5%#6 | -42.5%#6 | — | — | 37.8%#4 | — |
| SRZN | $367M#9 | — | — | 105.5x#7 | -67.4%#8 | -280.8%#14 | -1210.6%#8 | — | — | — | 123.0%#2 | — |
| KYTX | $320M#12 | — | 1.9x#6 | — | — | -26.5%#9 | — | -97.4%#10 | -107.1%#4 | — | -18.3%#11 | — |
| XFOR | $316M#13 | 2.2x#1 | 2.0x#7 | 9.0x#4 | 1273.2%#3 | -111.5%#13 | -247.4%#5 | -50.9%#8 | -582.0%#5 | — | -19.2%#12 | — |
| AGEN | $312M#14 | 2.3x#2 | — | 2.7x#1 | 10.4%#6 | 98.7%#1 | -17.7%#2 | — | — | — | 86.1%#3 | — |
| IPSC | $305M#15 | — | 1.3x#3 | 2.8x#2 | 1556.8%#2 | 92.4%#2 | -15.8%#1 | -4.1%#2 | -9.3%#1 | — | 195.5%#1 | — |
| EIKN | $326M#10 | — | 0.7x#1 | — | — | — | — | 0.0%#1 | — | — | — | — |
| SCTX | $323M#11 | — | — | — | — | — | — | — | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议